
Dan Krakoff
Partner and Chair of the Global Life Sciences Industry Practice at Arnold & Porter
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Aug 3, 2026
An Extensive Breakdown of the Pharmaceutical and Biologics Landscape
13:57
14:08
14:31
14:42
14:55

Dan KrakoffGUEST
Um, I mean, we've had five acting or, or actual CBER directors and six CDER directors in a relatively short period of time.

Dan KrakoffGUEST
We have some people in place now that are a lot more typical in terms of what we've seen in the past, um, uh, and some folks who are in place now that seem to be seeking a reset, uh, a regular order at least, um, a type of tenor to FDA.

Dan KrakoffGUEST
I just worry, is it gonna la-last past the midterm elections? Uh, because, you know, RFK Jr., secretary, has his views of the world.

Dan KrakoffGUEST
Um, uh, they were, you know, quite active in implementing those views, uh, through, um, the prior, um, commissioner and head of CBER and others.

Dan KrakoffGUEST
Um, and it-- we could easily go back to a state of chaos, and I think it's really important, um, that they at least recognize that there's a political liability to allowing FDA to lose its authority, uh, and, uh, you know, uh, really put FDA in the public eye.
16 MINS LATER
W
31:40Wayne PinesHOST
Uh, what's your view as to what's going on now, and especially what's happened in the last 18 months, uh, with this new administration?